The first patient has been dosed in a Phase 2 trial of BGE-102, an oral pill built on human aging research, aimed at preserving vision.
Diabetic macular edema doesn’t sound like a longevity story. It’s an eye condition, tied to diabetes, that causes fluid to build up and blur central vision, and it happens to be one of the leading causes of vision loss in working-age adults, affecting roughly a million people in the United States alone. But the molecule California-based company BioAge Labs just put into a patient’s bloodstream didn’t come out of eye research at all. It came out of digging through data on people who age unusually well.
BioAge announced that the first participant has been dosed in QUELL-DME, a Phase 2 trial evaluating its oral drug BGE-102 in adults with diabetic macular edema. Roughly 180 people will take part, testing the drug both alone and layered on top of standard anti-VEGF injections, with change in vision at 12 weeks as the main measure of success [1].
BGE-102 blocks a protein called NLRP3, which sits near the top of an inflammatory cascade tied to a strikingly wide range of age-related problems: cardiovascular disease, obesity and other metabolic disorders, neurodegenerative conditions and inflammation-driven eye diseases including DME and geographic atrophy.
BioAge didn’t find NLRP3 through eye research. The company’s discovery platform flagged it while analyzing human aging cohorts, data that showed people with lower NLRP3 activity tended to be the ones aging more slowly and living longer. That’s a fairly direct line from basic aging biology to a drug now sitting in someone’s bloodstream, even if it took a detour through ophthalmology to get there.
“NLRP3 is a compelling target in DME because it sits upstream of the inflammation that drives vascular leakage and vision loss,” said Dr Kristen Fortney, BioAge’s CEO and co-founder. “The disease affects about one million people in the United States and is a leading cause of vision loss in working-age adults. Standard care still requires repeated injections into the eye; many patients delay starting treatment, miss doses, or never achieve adequate disease control.”
Fortney said that the QUELL-DME study aims to answer the straightforward question of whether a once-daily oral dose of BGE-102 can improve vision. She noted that dosing the first participant represents a significant milestone for the program and added that the results from the trial will help guide further development for other NLRP3-driven retinal diseases, such as geographic atrophy.
Standard treatment for DME right now usually means regular eye injections, which are about as unpleasant as it sounds, and a real reason plenty of patients simply stop showing up for care. An oral, once-daily pill, assuming it works, removes a lot of that friction.
QUELL-DME is a three-arm, randomized trial, split roughly evenly between anti-VEGF injections plus an oral placebo, anti-VEGF plus 90mg of BGE-102 daily, and a sham injection plus 90mg of BGE-102 daily on its own. That design lets researchers see whether the drug works better as an add-on, as a standalone replacement or, less happily, not really at all. Topline results aren’t due until the second half of 2027, so this is patience-required territory.
Dr Paul Rubin, BioAge’s chief medical officer, laid out the thinking behind testing both roles at once: “NLRP3 sits upstream of key disease processes implicated in DME, including IL-1β and IL-18 release, pyroptosis, VEGF production, and disruption of the blood-retinal barrier. Prior interventional studies of intravitreal IL-6 inhibition provide clinical support for inflammation as a therapeutic target in macular edema. QUELL-DME’s three-arm design lets us evaluate the two potential roles for oral BGE-102 in DME: as monotherapy and as an add-on to anti-VEGF treatment.”
Rubin explained that because DME develops within the context of diabetes, systemic NLRP3 inhibition could provide ocular benefits by addressing both localized retinal inflammation and the underlying systemic inflammatory state that drives the condition.
This isn’t the only trial riding on BGE-102, either. The same molecule is being tested separately in QUELL-CV, a cardiovascular-focused study in people with obesity and elevated inflammation, which has already finished enrolling, with topline data expected later this year. An earlier Phase 1 study, in healthy volunteers and people with obesity, showed promising drops in hsCRP, a common blood marker of systemic inflammation.
The eye trial won’t read out for a while yet. Still, it’s a fairly clean example of how longevity-driven drug discovery is supposed to work in theory: start with what keeps people biologically younger for longer, follow the biology wherever it leads, and don’t be too surprised when it turns up somewhere as specific as a diabetic patient’s vision.
